Work

Phase I Study of the JAK2 V617F Inhibitor, LY2784544, in Patients with Myelofibrosis (MF), Polycythemia Vera (PV), and Essential Thrombocythemia (ET)

Year: 2011

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v118.21.2814.2814

Authors: Srdan Verstovsek, Ruben A. Mesa, Susanne Kloeker Rhoades, Jennifer L K Giles, Celine Pitou, Emma Jones, Richard A Walgren, Josef T. Prchal

Institutions: The University of Texas MD Anderson Cancer Center, Mayo Clinic, Mayo Clinic in Arizona, Eli Lilly (United States), Eli Lilly (United Kingdom), University of Utah

Language: English

Topic: Myeloproliferative Neoplasms: Diagnosis and Treatment

Subfield: Genetics (clinical)

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2554340669

FWCI: 3.977

Cites:

Cited by: 35

Related to: 10